Caterpillar bids for Australia’s RPMGlobal- AFR
MELBOURNE - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), a biopharmaceutical company valued at $4.8 billion, announced today the appointment of Dr. Paul Schaffer as Chief Technology Officer (CTO), effective immediately. According to InvestingPro data, the company maintains a "GREAT" financial health score, positioning it well for continued growth in the radiopharmaceutical sector. Dr. Schaffer, formerly the CTO at ARTMS Inc., which Telix acquired in 2024, brings extensive experience from his role at Canada’s TRIUMF particle accelerator research center.
In his new position at Telix, Dr. Schaffer will focus on leveraging technology to enhance the company’s radiopharmaceutical research, development, and clinical applications. His areas of expertise include chemistry, physics, artificial intelligence (AI), dosimetry, and data analytics. This move aims to complement the ongoing R&D efforts led by Telix’s Chief Scientist, Dr. Michael Wheatcroft, and his team.
Dr. Schaffer expressed enthusiasm for his new role, especially as Telix progresses toward its goal of transforming patient care through innovation. The company has demonstrated strong execution, with revenue growth of 56% over the last twelve months. Dr. Christian Behrenbruch, Telix Managing Director and Group CEO, praised Dr. Schaffer’s innovative contributions to life sciences technology and his role in large-scale isotope production.
Telix specializes in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals, addressing unmet medical needs in oncology and rare diseases. The company operates internationally, with headquarters in Melbourne and additional operations in the United States, Brazil, Canada, Europe, and Japan. With the next earnings report scheduled for May 19, investors can gain deeper insights into the company’s performance through InvestingPro, which offers 14 additional exclusive tips and comprehensive financial analysis.
The appointment of Dr. Schaffer as CTO is part of Telix’s commitment to leading innovation in the radiopharmaceutical sector. This information is based on a press release statement from Telix Pharmaceuticals Limited.
In other recent news, Telix Pharmaceuticals Limited has announced several significant developments. The company has initiated the Phase 1 ZOLAR1 trial for its TLX300-CDx, targeting advanced soft tissue sarcoma. This trial aims to assess safety and determine the optimal dose, leveraging a theranostic approach combining therapy and diagnostics. Additionally, the U.S. Food and Drug Administration has approved Telix’s new prostate cancer imaging agent, Gozellix®, enhancing access to advanced PSMA-PET imaging for prostate cancer patients. The imaging agent is designed to improve clinic efficiency and is expected to be eligible for full reimbursement, potentially reducing patient costs.
Telix has also completed the acquisition of assets and technology from ImaginAb, Inc., valued at an upfront cost of $45 million. This acquisition includes a biologics technology platform and therapeutic candidates targeting cancer proteins, expanding Telix’s precision medicine offerings. The deal comprises a cash payment, equity, and contingent payments based on future milestones. These developments reflect Telix’s ongoing commitment to innovation in therapeutic and diagnostic radiopharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.